Taho Pharmaceuticals Ltd.

Research Taho Pharmaceuticals Ltd. (6467.TW) on Bullrun: market cap TWD 11.16B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is TWD 11.16B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025TWD 8.41M-TWD 214.40M-TWD 210.04M64.3%-4.16TWD 339.98MTWD 11.31MTWD 423.70M
FY2024TWD 0-TWD 167.44M-TWD 165.73Mn/a-3.69TWD 245.87MTWD 16.65MTWD 516.20M
FY2023TWD 1.07M-TWD 120.68M-TWD 107.10M-6.8%-3.12TWD 151.71MTWD 21.62MTWD 206.69M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-11-21TWD 11.16Bn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 TWD.

About Taho Pharmaceuticals Ltd.

Taho Pharmaceuticals Ltd., a commercial-stage pharmaceutical company, focuses on the development of drug delivery systems in transdermal and transmucosal systems in Taiwan. The company offers TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Its pipeline includes TAH3311 Apixaban oral film, which is in phase III; TAH3341, an anticoagulant apixaban ODF extended-release film, which is in preclinical stage.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Taho Pharmaceuticals Ltd.'s market cap?

Taho Pharmaceuticals Ltd.'s market capitalization is TWD 11.16B.

What does Taho Pharmaceuticals Ltd. do?

Taho Pharmaceuticals Ltd., a commercial-stage pharmaceutical company, focuses on the development of drug delivery systems in transdermal and transmucosal systems in Taiwan. The company offers TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Its pipeline includes TAH3311 Apixaban oral film, which is in phase III; TAH3341, an anticoagulant apixaban ODF extended-release film, which is in preclinical stage.